Adenoviral vectors: the delivery workhorse of genetic vaccines and gene therapy
How replication-deficient adenoviral vectors work, why suspension bioreactors and the plasmid-to-vector GMP chain decide who can manufacture them, and what platform families like Ad5 and GRAd actually share.
An adenoviral vector is a deal struck with a common pathogen. The virus is reduced to a delivery shell — replication genes removed so the particle can enter a cell, hand over an expression cassette, and go no further — and the deleted capacity is spent carrying cargo: an antigen gene for a vaccine, a corrective gene for a therapy. The host cell does the rest, which is why the platform reads like a manufacturing contract rather than a drug design. Immunogenicity, once the obstacle, became a feature: a vector that provokes innate attention is exactly what a vaccine wants, and the same property is what gene-therapy programs must manage down.
The industrial logic rests on one biological fact: adenoviruses grow to high titers in suspension culture. That single property moved vector manufacturing out of adherent-cell factories and into single-use bioreactors measured in thousands of litres, which is why a mid-size European pure-play can promise batch fill-finish of up to 3,500 vials from 2,000 L behind six isolated GMP suites of 3,470 square metres. Scale is not the whole story, because a vector campaign inherits its quality from its inputs. The expression cassette arrives as GMP-grade plasmid DNA, and plasmid supply industrialized on its own schedule: a dedicated commercial plasmid facility of 6,400 square metres in Zhenjiang now backs 16,000 litres of GMP capacity that has carried more than 140 IND clearances — the quiet precondition of every vector program behind it.
Platform families are where the economics compound. One capsid backbone, re-targeted by swapping the expression cassette, serves a vaccine against one pathogen, a vaccine against another, and a gene-therapy indication after that. CanSino Biologics built its position as a global pioneer of adenoviral-vector vaccines on the Ad5 platform and now couples it to lines in Mexico, Pakistan and Malaysia, a Shanghai facility sized for 100 million doses per year, and the market-by-market certificate stack — Malaysian NAPRA GMP, Indonesian Halal certification — that commercial supply at population scale actually requires. ReiThera’s GRAd line descends from the Okairos team GSK acquired in 2014, with platforms validated alongside GSK and in large COVID-19 vaccine trials. OBiO Technology in Shanghai packages plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I–III to commercial supply, reporting a fully commercial closed loop in 2026.
What the platform cannot yet do is worth stating plainly. Adenoviral immunity in the human population is real, so repeat dosing runs against pre-existing antibodies — the reason higher-serotype and chimpanzee-derived backbones exist at all. Transgene size fits inside the capsid’s fixed budget. And the delivery is episodic: the vector does what it is asked once, then the immune system clears the machinery. The field’s answers — platform families, alternative serotypes, immune-management regimens — are engineering around a biology that is unlikely to be argued away. The manufacturing map, not the capsid map, is where the field’s near-term competition is being decided: who can run suspension GMP at 2,000 litres, feed it from an industrial plasmid plant, and put fill lines close to the markets their certificates must satisfy.
Evidence and practice
Adenoviral vector gene therapy — the technology dossier: sources with check dates, maturity, what it replaces, how to implement it, who delivers it.